A recently approved drug may offer complete corneal healing for some patients with neurotrophic keratitis.
Cenegermin, which will be marketed as Oxervate, is a topical eye drop. Ophthalmologist Wiley Chambers, MD, of the FDA’s Center for Drug Evaluation and Research, said neurotrophic keratitis can have a devastating effect on patients. “In the past it has often been necessary to turn to surgical interventions; these treatments are usually only palliative in this disease,” Chambers said in a statement, calling cenegermin a “major advance.”
Voelker R. New Drug Treats Rare, Debilitating Neurotrophic Keratitis. JAMA. 2018;320(13):1309. doi:https://doi.org/10.1001/jama.2018.14132
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: